summary of the Text: PUF60 as a Therapeutic Target in Triple-Negative Breast Cancer (TNBC)
This text details the revelation of PUF60, a poly(U)-binding splicing factor, as a crucial protein for the survival of Triple-Negative Breast Cancer (TNBC) cells and a potential therapeutic target. Here’s a breakdown of the key findings:
* PUF60 is Essential for TNBC Viability: A genome-wide CRISPR/Cas9 screening identified PUF60 as a key RBP essential for TNBC cell survival.
* Mechanism of Action: PUF60 regulates splicing, specifically the inclusion of exons in proliferation-related transcripts. Disrupting PUF60 leads to exon skipping, reduced gene expression necessary for survival, DNA damage, and apoptosis in TNBC cells.
* TNBC Specific Vulnerability: TNBC cells, already prone to replication stress and DNA repair deficiencies, are particularly sensitive to disruptions in PUF60-mediated splicing. Normal breast cells are largely unaffected.
* Tumor Suppression Demonstrated: Loss of PUF60 function inhibited tumor growth and even caused regression in both in vitro and in vivo models.
* Therapeutic Potential:
* Direct Targeting: PUF60 itself, or its interacting proteins, could be targeted with small molecules.
* Combination Therapy: Combining splicing modulation with existing chemotherapies could overcome TNBC’s tendency to relapse and develop resistance. Impaired splicing could increase DNA damage,pushing cells beyond their repair capacity.
* Broader Implications: This research expands the scope of targetable cancer dependencies to include RNA splicing mechanisms, opening new avenues for drug development.
In essence, the study highlights PUF60 as a promising therapeutic target for TNBC due to its critical role in splicing, the specific vulnerability of TNBC cells, and the potential for both direct and combination therapies.
